Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-patient study of olipudase alfa in Japanese ASMD patient post-DFI12712
jRCT2031210279Completed
- Sponsor
- Sanofi
- Start
- Sep 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of olipudase alfa in acid sphingomyelinase deficiency (ASMD), sponsored by Sanofi. Primary endpoint: Adverse events. Started Sep 2021; status: completed.
02
Drugs
olipudase alfa
03
Conditions
acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on jRCT2031210279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210279.